Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Atherosclerosis|November 9, 2011
Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cellsThore Dietrich, Thomas Hucko, Christiane Schneemann, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2012
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignanciesPaola A Erba, Martina Sollini, Enrico Orciuolo, et al.Blood|January 10, 2009
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patientsStefanie Sauer, Paola A Erba, Mario Petrini, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 18, 2014
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphomaLuigi Aloj, Laura D'Ambrosio, Michela Aurilio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter studyMiklos Pless, Karim Belhadj, Hans D Menssen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myelomaHans D Menssen, Adriana Sakalová, Aurélie Fontana, et al.Journal of Surgical Oncology|June 8, 2012
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanomaFrancesco Papadia, Valeria Basso, Roberto Patuzzo, et al.Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanomaThomas K Eigentler, Benjamin Weide, Filippo de Braud, et al.The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.Pageof 4